Company: BFRG
Filing Date: 2025-12-01
Form Type: 424B3
Source: 0001493152-25-025570
Chunk: 8

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-12-01
Form: 424B3
Chunk 8
---
 provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies, but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Recent Developments

ATM Sales

On April 25, 2025, we entered into an At-The-Market (“ATM”) Sales Agreement (the “ATM Agreement”) with BTIG, LLC, as sales agent (the “Agent”), with respect to an ATM offering program under which we may offer and sell through the Agent, from time to time at our sole discretion, shares (the “Shares”) of our common stock, par value $0.00001 per share (the “Common Stock”). From April 25, 2025 through October 6, 2025, we sold 755,116 shares of our Common Stock through our ATM program for aggregate net proceeds of $1.15 million.

Eleison Pharmaceuticals Collaboration

On February 27, 2025, the Company entered into a collaboration agreement with Eleison Pharmaceuticals Inc. (“Eleison”), a Phase III oncology company developing novel chemotherapeutic treatments for rare cancers. Under this agreement, BullFrog will utilize its proprietary BullFrog Data Networks™ platform, powered by the bfLEAP® engine, to support Eleison’s clinical development programs. The collaboration is designed to enhance clinical trial efficiency, extract actionable insights from historical and ongoing data, and improve the strategic planning of Eleison’s oncology pipeline.

As part of the collaboration, the Company will deliver services that focus on clustering patients using available clinical features to identify patient subsets and understand their relative responses to drug treatment. Additionally, BullFrog will perform real-time analysis of safety data from Eleison’s ongoing Phase III clinical trial of glufosfamide. The bfLEAP® platform will be utilized to support three primary objectives: (1) assess the current trajectory of the ongoing trial with respect to safety endpoints; (2)